Excuse me for interjecting myself in here, but I have to say, I couldn't care less what joe retail says about value, as long as their focus sidesteps or demonstrates a full academic understanding of what they own. It's understanding the significance of how meticulously the company has carved out ownership, not only of its core platform, but also in combination with existing blockbuster modalities, which forces BP to come to NWBO, whether BP likes the deal or not. You're absolutely right, we see BP's spending top dollar on preliminary mouse models, buying up immunologic treatment components, not standalone, which only deepens their interdependence on a mature DCVax platform. What does NWBO have to show for two decades of development time, DATA. Setting aside future trials, NWBO hasn't stopped accruing real-life treatment data for the last several years through the UK specials program. That data sits behind a firewall. That's a monsterous blindspot for shorts. How many pre revenue biotechs have that luxury? After all, it's an ongoing LIVING TRIAL. The longer it goes the greater the statistical power generated. Andrew illlustrates the elegance of platform's progression, which joe retail, especially shorts are incapable, nor paid to want to understand. If they were, they wouldn't spend their entire lives as anonymous cartoon characters, at best, posting juvenile b.s. 24/7. "SP", "dilusion" "grift" "nobody cares"... etc. are SyOp key words to distract attention away from the intrinsic value the company has built. I invested in this company ahead of it going commercial, and tracking completed milestones towards that eventuality. The rest is noise.
Market Data 
Markets 
AI
